Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
A6ND01
UPID:
JUNO_HUMAN
Alternative names:
Folate receptor 4; Folate receptor delta; IZUMO1 receptor protein JUNO
Alternative UPACC:
A6ND01
Background:
Sperm-egg fusion protein Juno, also known as Folate receptor 4, Folate receptor delta, and IZUMO1 receptor protein JUNO, plays a pivotal role in fertilization. It serves as the receptor for IZUMO1, present on the oocyte surface, facilitating species-specific gamete recognition essential for successful fertilization. This interaction, while crucial for sperm-egg adhesion, does not directly induce cell fusion.
Therapeutic significance:
Understanding the role of Sperm-egg fusion protein Juno could open doors to potential therapeutic strategies.